306 related articles for article (PubMed ID: 33252851)
1. Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma.
Shen R; Xu PP; Wang N; Yi HM; Dong L; Fu D; Huang JY; Huang HY; Janin A; Cheng S; Wang L; Zhao WL
Clin Transl Med; 2020 Nov; 10(7):e221. PubMed ID: 33252851
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma.
Zhu Y; Fu D; Shi Q; Shi Z; Dong L; Yi H; Liu Z; Feng Y; Liu Q; Fang H; Cheng S; Wang L; Tian Q; Xu P; Zhao W
Front Immunol; 2022; 13():842439. PubMed ID: 35401516
[TBL] [Abstract][Full Text] [Related]
3. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
Shen R; Fu D; Dong L; Zhang MC; Shi Q; Shi ZY; Cheng S; Wang L; Xu PP; Zhao WL
Signal Transduct Target Ther; 2023 Apr; 8(1):145. PubMed ID: 37032379
[TBL] [Abstract][Full Text] [Related]
4. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
[TBL] [Abstract][Full Text] [Related]
5. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA; Olszewski AJ
Curr Treat Options Oncol; 2018 Jun; 19(8):38. PubMed ID: 29931605
[TBL] [Abstract][Full Text] [Related]
6. The Mutation of
Guo D; Hong L; Ji H; Jiang Y; Lu L; Wang X; Huang H
J Inflamm Res; 2022; 15():1757-1769. PubMed ID: 35300216
[TBL] [Abstract][Full Text] [Related]
7. Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes.
Xie Z; Qin Y; Chen X; Yang S; Yang J; Gui L; Liu P; He X; Zhou S; Zhang C; Tang L; Shi Y
Target Oncol; 2024 Apr; ():. PubMed ID: 38643457
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma.
Guan T; Zhang M; Liu X; Li J; Xin B; Ren Y; Yang Y; Wang H; Zhao M; Huang Y; Guo X; Du J; Qian W; Su L
Front Oncol; 2022; 12():1003957. PubMed ID: 36465410
[TBL] [Abstract][Full Text] [Related]
9.
Vermaat JS; Somers SF; de Wreede LC; Kraan W; de Groen RAL; Schrader AMR; Kerver ED; Scheepstra CG; Berenschot H; Deenik W; Wegman J; Broers R; de Boer JD; Nijland M; van Wezel T; Veelken H; Spaargaren M; Cleven AH; Kersten MJ; Pals ST
Haematologica; 2020; 105(2):424-434. PubMed ID: 31123031
[TBL] [Abstract][Full Text] [Related]
10. SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups.
Guo B; Huang Y; Duan Y; Liao C; Cen H
Cancer Med; 2022 Mar; 11(5):1281-1291. PubMed ID: 35106936
[TBL] [Abstract][Full Text] [Related]
11. [Clinical characteristics and prognosis of primary and secondary diffuse large B-cell lymphoma of the pancreas].
Huo YJ; Zhang MC; Shi Q; Qin W; Shi ZY; Wang L; Cheng S; Xu PP; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):55-61. PubMed ID: 36987724
[No Abstract] [Full Text] [Related]
12. Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.
Li P; Chai J; Chen Z; Liu Y; Wei J; Liu Y; Zhao D; Ma J; Wang K; Li X; Shao Y; Gong L; Zhang W; Guo S; Yan Q; Li M; Fan L; Wang Z
Front Oncol; 2021; 11():622648. PubMed ID: 33747936
[TBL] [Abstract][Full Text] [Related]
13. A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88
Deng T; Zhang S; Xiao M; Gu J; Huang L; Zhou X
Cancer Med; 2024 Feb; 13(4):e7005. PubMed ID: 38457222
[TBL] [Abstract][Full Text] [Related]
14. Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma.
Lee MJ; Koff JL; Switchenko JM; Jhaney CI; Harkins RA; Patel SP; Dave SS; Flowers CR
Cancer; 2020 Aug; 126(15):3493-3503. PubMed ID: 32469082
[TBL] [Abstract][Full Text] [Related]
15. Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.
Chen Z; Zou Y; Liu W; Guan P; Tao Q; Xiang C; Zhang W; Ye Y; Yan J; Zhao S
Am J Surg Pathol; 2020 Apr; 44(4):444-455. PubMed ID: 31609782
[TBL] [Abstract][Full Text] [Related]
16. Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma.
Huo YJ; Xu PP; Wang L; Zhong HJ; Fu D; Shi Q; Cheng S; Wang S; Zhang MC; Zhao WL
Biomark Res; 2022 Jul; 10(1):51. PubMed ID: 35879731
[TBL] [Abstract][Full Text] [Related]
17. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.
Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S
Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251
[TBL] [Abstract][Full Text] [Related]
18. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T
Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547
[TBL] [Abstract][Full Text] [Related]
19. MYD88
Chen R; Zhou D; Wang L; Zhu L; Ye X
Ther Adv Hematol; 2022; 13():20406207211072839. PubMed ID: 35126963
[TBL] [Abstract][Full Text] [Related]
20. The impact of MYD88 and PIM1 in mature large B-cell non-Hodgkin lymphomas: Defining element of their evolution and prognosis.
Cristian M; Așchie M; Mitroi AF; Deacu M; Boșoteanu M; Bălțătescu GI; Stoica AG; Nicolau AA; Enciu M; Crețu AM; Caloian AD; Orășanu CI; Poinăreanu I
Medicine (Baltimore); 2024 Feb; 103(6):e36269. PubMed ID: 38335426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]